Glaukos Corp
NYSE:GKOS

Watchlist Manager
Glaukos Corp Logo
Glaukos Corp
NYSE:GKOS
Watchlist
Price: 124.71 USD 5.06% Market Closed
Market Cap: $7.2B

Operating Margin

-18.8%
Current
Improving
by 14.6%
vs 3-y average of -33.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-18.8%
=
Operating Income
$-88.4m
/
Revenue
$469.8m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-18.8%
=
Operating Income
$-88.4m
/
Revenue
$469.8m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Glaukos Corp
NYSE:GKOS
6.8B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
187.1B USD
Loading...
US
Abbott Laboratories
NYSE:ABT
184.5B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
139.3B USD
Loading...
US
Stryker Corp
NYSE:SYK
136.2B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
129.3B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
57.8B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
47.4B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
55.2B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
47.9B USD
Loading...
US
Resmed Inc
NYSE:RMD
37.5B USD
Loading...

Market Distribution

Lower than 76% of companies in the United States of America
Percentile
24rd
Based on 14 112 companies
24rd percentile
-18.8%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Glaukos Corp
Glance View

Founded in 1998, Glaukos Corporation has carved a niche within the highly specialized arena of ophthalmic medical technology. Enveloped in the nuances of eye health, Glaukos initially set its sights on transforming the treatment of glaucoma, a prevalent yet often devastating eye condition. The company pioneered the development of minimally invasive surgical devices, introducing the iStent, which offers a less invasive procedure compared to traditional glaucoma surgeries. This implantable device works by enhancing the natural outflow of fluid from the eye, ultimately reducing intraocular pressure, a key factor in managing glaucoma. Glaukos succeeded where many had faltered by coupling sophisticated technology with a deep understanding of its ophthalmologist customer base, facilitating smoother surgical processes and better patient outcomes. The business model of Glaukos is deeply intertwined with continuous innovation and robust partnerships with healthcare professionals. Revenue primarily stems from the sale of its flagship products—devices and systems designed for both glaucoma treatment and other corneal health therapies. The company achieves this through a combination of direct sales and strategic global partnerships, expanding its market reach beyond domestic borders. Furthermore, Glaukos invests significantly in research and development, extending its portfolio and venturing into adjacent fields like corneal disorders. This strategy not only secures its position as an industry leader but also catalyzes sustainable growth by addressing broader aspects of ophthalmic care, thus ensuring a steady stream of revenue flows as they remain at the cutting edge of eye healthcare solutions.

GKOS Intrinsic Value
34.25 USD
Overvaluation 73%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-18.8%
=
Operating Income
$-88.4m
/
Revenue
$469.8m
What is Glaukos Corp's current Operating Margin?

The current Operating Margin for Glaukos Corp is -18.8%, which is above its 3-year median of -33.4%.

How has Operating Margin changed over time?

Over the last 3 years, Glaukos Corp’s Operating Margin has increased from -33.9% to -18.8%. During this period, it reached a low of -43.3% on Mar 31, 2023 and a high of -18.8% on Sep 30, 2025.

Back to Top